FDA OKs new use for Melinta's Baxdela; shares down 26% premarket on potential capital raise

FDA OKs new use for Melinta's Baxdela; shares down 26% premarket on potential capital raise

Submitted by admin on October 25, 2019 - 10:37am
Source: 
Seeking Alpha
News Tags: 
Melinta Therapeutics
FDA
Baxdela
community-acquired bacterial pneumonia
Headline: 
FDA OKs new use for Melinta's Baxdela; shares down 26% premarket on potential capital raise
snippet: 

The FDA approves Melinta Therapeutics' (NASDAQ:MLNT) BAXDELA (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP).

Do Not Allow Advertisers to Use My Personal information